CTT Pharma CEO Ryan Khouri outlined the company's plans to advance its patented micelle thin-film technology toward manufacturing and commercialization in a letter to shareholders. The company is preparing to file an S-1 registration statement to access funding from an equity line and become an SEC reporting company, a move expected to increase transparency and attract more investors. Khouri emphasized careful management of share count and dilution during this funding process.
The capital raised will be directed toward manufacturing the company's oral dissolvable strip products, including micelle-encapsulated vitamins, bioactive supplements, and nicotine strips, with production targeted for 2026. CTT Pharma is currently strengthening its team with regulatory experts to navigate approval processes for North American sales and plans to hire additional personnel with commercial product launch experience. The company is also in the process of identifying a manufacturing facility in the first quarter, followed by equipment acquisition for production.
A partnership with Johns Hopkins University continues under a National Institutes of Health grant exploring the technology as a smoking cessation alternative, though clinical trial funding remains pending. The company noted that its manufacturing and commercialization timeline is not dependent on this NIH decision. The company recently achieved a scientific milestone with the acceptance of a peer-reviewed manuscript for publication on December 15, 2025. The paper, co-authored by scientist Dr. Katharine Cole and founder Dr. Pankaj Modi, provides a comprehensive review of micelle/oral dissolvable strip technology research.
This publication is expected to increase visibility and understanding of the scientific principles behind CTT's platform among shareholders, potential partners, and the scientific community. Khouri also mentioned ongoing efforts to strengthen the company's patent portfolio and plans for a first-quarter conference call to discuss progress and upcoming initiatives. With capital becoming available, the company is expanding its team, advancing toward manufacturing, and defining regulatory pathways to bring its drug delivery technology to market. The move toward SEC reporting status represents a significant step in establishing credibility and accessing public markets, which could accelerate the development of innovative drug delivery systems that bypass traditional pill and liquid formulations.
